Evaluation of Parkinson Disease and Alzheimer Disease with the Use of Neuromelanin MR Imaging and ¹²³I-Metaiodobenzylguanidine Scintigraphy

REFERENCES

1. 1.↵
   1. Pahwa R,
   2. Lyons KE

   . Early diagnosis of Parkinson's disease: recommendations from diagnostic clinical guidelines. Am J Manag Care 2010;16(Suppl):S94–99

   PubMedWeb of Science
2. 2.↵
   1. Fedorow H,
   2. Tribl F,
   3. Halliday G,
   4. et al

   . Neuromelanin in human dopamine neurons; comparison with peripheral melanins and relevance to Parkinson's disease. Prog Neurobiol 2005;75:109–24

   CrossRefPubMedWeb of Science
3. 3.↵
   1. Zecca L,
   2. Tampellini D,
   3. Gerlach M,
   4. et al

   . Substantia nigra neuromelanin: structure, synthesis, and molecular behavior. Mol Pathol 2001;54:414–18

   Abstract/FREE Full Text
4. 4.↵
   1. Damier P,
   2. Hirsch EC,
   3. Agid Y,
   4. et al

   . The substantia nigra of the human brain, II: patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain 1999;122:1437–48

   Abstract/FREE Full Text
5. 5.↵
   1. Fearnley JM,
   2. Lees AJ

   . Aging and Parkinson's disease: substantia nigra regional selectivity. Brain 1991;114:2283–301

   Abstract/FREE Full Text
6. 6.↵
   1. Halliday GM,
   2. McRitchie DA,
   3. Cartwright HR,
   4. et al

   . Midbrain neuropathology in idiopathic Parkinson's disease and diffuse Lewy body disease. J Clin Neurosci 1996;3:52–60

   CrossRefPubMedWeb of Science
7. 7.↵
   1. Förstl H,
   2. Burns A,
   3. Luthert P,
   4. et al

   . Clinical and neuropathological correlates of depression in Alzheimer's disease. Psychol Med 1992;22:877–84

   PubMedWeb of Science
8. 8.↵
   1. Sasaki M,
   2. Shibata E,
   3. Tohyama K,
   4. et al

   . Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson's disease. NeuroReport 2006;17:1215–18

   CrossRefPubMedWeb of Science
9. 9.↵
   1. Mann DM,
   2. Yates PO

   . Possible role of neuromelanin in the pathogenesis of Parkinson's disease. Mech Ageing Dev 1983;21:193–203

   CrossRefPubMedWeb of Science
10. 10.↵
    1. Schwarz ST,
    2. Rittman T,
    3. Gontu V,
    4. et al

    . T1-weighted MRI shows stage-dependent substantia nigra signal loss in Parkinson's disease. Mov Disord 2011;26:1633–38

    CrossRefPubMed
11. 11.↵
    1. Kashihara K,
    2. Shinya T,
    3. Higaki F

    . Neuromelanin magnetic resonance imaging of nigral volume loss in patients with Parkinson's disease. J Clin Neurosci 2011;18:1093–96

    CrossRefPubMed
12. 12.↵
    1. Wieland DM,
    2. Brown LE,
    3. Rogers WL,
    4. et al

    . Myocardial imaging with a radioiodinated norepinephrine storage analog. J Nucl Med 1981;22:22–31

    Abstract/FREE Full Text
13. 13.↵
    1. Druschky A,
    2. Hilz MJ,
    3. Platsch G,
    4. et al

    . Differentiation of Parkinson's disease and multiple system atrophy in early disease stages by means of I-123-MIBG-SPECT. J Neurol Sci 2000;175:3–12

    CrossRefPubMedWeb of Science
14. 14.↵
    1. Spiegel J,
    2. Hellwig D,
    3. Farmakis G,
    4. et al

    . Myocardial sympathetic degeneration correlates with clinical phenotype of Parkinson's disease. Mov Disord 2007;22:1004–08

    CrossRefPubMedWeb of Science
15. 15.↵
    1. Hoehn MM,
    2. Yahr MD

    . Parkinsonism: onset, progression and mortality. Neurology 1967;17:427–42

    CrossRefPubMed
16. 16.↵
    1. Imai Y,
    2. Hasegawa K

    . The revised Hasegawa's dementia scale (HDS-R) - evaluation of its usefulness as a screening test for dementia. J Hong Kong Coll Psychiatr 1994;4:20–24
17. 17.↵
    1. Tanabe Y,
    2. Harada H,
    3. Sugihara S,
    4. et al

    . 123I-metaiodobenzylguanidine myocardial scintigraphy in panic disorder. J Nucl Med 2004;45:1305–08

    Abstract/FREE Full Text
18. 18.↵
    1. Tanaka M,
    2. Aihara Y,
    3. Ikeda S,
    4. et al

    . Neuromelanin-related contrast in the substantia nigra semiquantitatively evaluated by magnetic resonance imaging at 3T: comparison between normal aging and Parkinson disease. Clin Neurol 2011;51:14–20
19. 19.↵
    1. Braak H,
    2. Del Tredici K,
    3. Rub U,
    4. et al

    . Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197–211

    CrossRefPubMedWeb of Science
20. 20.↵
    1. Halliday GM,
    2. Ophof A,
    3. Broe M,
    4. et al

    . α-Synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease. Brain 2005;128:2654–64

    Abstract/FREE Full Text
21. 21.↵
    1. Isaias IU,
    2. Marotta G,
    3. Pezzoli G,
    4. et al

    . Enhanced catecholamine transporter binding in the locus coeruleus of patients with early Parkinson disease. BMC Neurol 2011;11:88

    CrossRefPubMed
22. 22.↵
    1. Rommelfanger KS,
    2. Weinshenker D

    . Norepinephrine: the redheaded stepchild of Parkinson's disease. Biochem Pharmacol 2007;74:177–90

    CrossRefPubMedWeb of Science
23. 23.↵
    1. Weinshenker D

    . Functional consequences of locus coeruleus degeneration in Alzheimer's disease. Curr Alzheimer Res 2008;5:342–45

    CrossRefPubMedWeb of Science
24. 24.↵
    1. Haneka MT,
    2. Nadrigny F,
    3. Regen T,
    4. et al

    . Locus ceruleus controls Alzheimer's disease pathology by modulating microglial functions through norepinephrine. Proc Natl Acad Sci U S A 2010;107:6058–63

    Abstract/FREE Full Text
25. 25.↵
    1. Busch C,
    2. Bohl J,
    3. Ohm TG

    . Spatial, temporal and numeric analysis of Alzheimer changes in the nucleus ceruleus. Neurobiol Aging. 1997;18:401–06

    CrossRefPubMedWeb of Science
26. 26.↵
    1. Nakajima K,
    2. Yoshita M,
    3. Matsuo S,
    4. et al

    . Iodine-123-MIBG sympathetic imaging in Lewy-body diseases and related movement disorders. J Nucl Med Mol Imaging 2008;52:378–87
27. 27.↵
    1. Okada Y,
    2. Ito Y,
    3. Aida J,
    4. et al

    . Lewy bodies in the sinoatrial nodal ganglion: clinicopathological studies. Pathol Int 2004;54:682–87

    CrossRefPubMed
28. 28.↵
    1. Orimo S,
    2. Takahashi A,
    3. Uchihara T,
    4. et al

    . Degeneration of cardiac sympathetic nerve begins in the early disease process of Parkinson's disease. Brain Pathol 2007;17:24–30

    CrossRefPubMedWeb of Science
29. 29.↵
    1. Rascol O,
    2. Schelosky L

    . ¹²³I-metaiodobenzylguanidine scintigraphy in Parkinson's disease and related disorders. Mov Disord 2009;24(Suppl 2):S732–41

    CrossRefPubMedWeb of Science
30. 30.↵
    1. Watanabe M,
    2. Takeda T,
    3. Nakamagoe K,
    4. et al

    . Sequential imaging analysis using MIBG scintigraphy revealed progressive degeneration of cardiac sympathetic nerve in Parkinson's disease. Eur J Neurol 2011;18:1010–13

    CrossRefPubMed